ENYO Pharma
PrivateLast Round
Series C
Extension
Jun 12, 2025
Total Funding Raised
$117.57M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
ENYO Pharma operates in Healthcare & Life Sciences and is based in Lyon. Its latest recorded funding round was a Series C Extension round in June 2025.
ENYO Pharma is a biotechnology company that develops innovative small molecule therapeutics by mimicking viral strategies to modulate host cellular functions for the treatment of rare kidney and chronic liver diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ENYO Pharma Comparables
Compare ENYO Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Eloxx Pharmaceuticals, Inc. | 76% | |
| Regulus Therapeutics Inc. | 74% | |
| Gilead Sciences | 73% |
For institutional investors. Book with your work email.
ENYO Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Jun 12, 2025 | ||||
| Series C | Jan 3, 2024 | ||||
| Series B | Jun 4, 2018 | ||||
| Grant | Dec 5, 2016 | ||||
| Series A | Feb 2, 2016 | ||||
Seed | Feb 2, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ENYO Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Commission (Horizon Europe) | Grant |
| Andera Partners | Series C Extension, Series C, Series B |
| Inserm Transfert | Series A, Seed, Series B |
| Morningside Ventures | Series A, Series B, Series C Extension, Series C |
| OrbiMed | Series C Extension, Series C, Series B |
| Vesalius Biocapital Partners | Series C Extension |
| Sofinnova Partners | Series B, Series A, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 36% MoM.
- Jun 12, 2025
ALPESTRIA-1 Phase 2 study shows continued progress in Alport syndrome patients.
For institutional investors. Book with your work email.
ENYO Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ENYO Pharma's valuation, stock price, and market status.
Is ENYO Pharma a public or private company?
ENYO Pharma is a private company.
What is the current stock price of ENYO Pharma?
ENYO Pharma is a private company, so its shares have no public market price. Caplight tracks ENYO Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ENYO Pharma worth (valuation)?
Valuation information for ENYO Pharma is not publicly available.
Can I buy ENYO Pharma stock?
ENYO Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ENYO Pharma's last funding round?
ENYO Pharma's most recent funding round was Series C Extension on June 12, 2025.
Who are the main investors in ENYO Pharma?
Key investors in ENYO Pharma include Morningside Ventures, OrbiMed, Vesalius Biocapital Partners, Sofinnova Partners.
Will ENYO Pharma IPO soon?
No public IPO plans have been announced for ENYO Pharma.
How can I track ENYO Pharma secondary market activity?
Caplight tracks bids, offers, and trades in ENYO Pharma's shares on secondary markets.